Literature DB >> 7527814

Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins.

G S Firestein1, D A Bullough, M D Erion, R Jimenez, M Ramirez-Weinhouse, J Barankiewicz, C W Smith, H E Gruber, K M Mullane.   

Abstract

Adenosine and adenosine analogues exhibit anti-inflammatory effects in vitro and in vivo, but their usefulness is limited by profound cardiovascular side effects. Therefore, we synthesized inhibitors of an enzyme involved in adenosine metabolism, adenosine kinase (AK) (EC 2.7.1.20), to enhance endogenous adenosine concentrations at sites of inflammation. GP-1-515 (4-amino-1-(5-amino-5-deoxy-1-beta-D- ribofuranosyl)-3-bromo-pyrazolo[3,4-d]pyrimidine), a novel AK inhibitor, decreased adhesion of activated human neutrophils to cultured endothelial cell monolayers by increasing local adenosine levels. The mechanism of inhibition in this assay seemed to involve selectin blockade and was independent of the beta 2 integrins. GP-1-515 and 2-chloroadenosine (a nonmetabolizable adenosine analogue) had no effect on the surface expression or shedding of adhesion molecules. An agent that disrupts the cytoskeleton, cytochalasin B, mimicked the effect of adenosine on cell adhesion. Interactions between L-selectin and the neutrophil cytoskeleton might be altered by adenosine and could contribute to adenosine-mediated adhesion inhibition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7527814

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Regulation of neutrophil function by adenosine.

Authors:  Kathryn E Barletta; Klaus Ley; Borna Mehrad
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

2.  Bruceine B, a potent inhibitor of leukocyte-endothelial cell adhesion.

Authors:  N Utoguchi; T Nakata; H H Cheng; K Ikeda; H Makimoto; Y Mu; S Nakagawa; M Kobayashi; I Kitagawa; T Mayumi
Journal:  Inflammation       Date:  1997-04       Impact factor: 4.092

Review 3.  Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.

Authors:  Bruce N Cronstein; Michail Sitkovsky
Journal:  Nat Rev Rheumatol       Date:  2016-11-10       Impact factor: 20.543

4.  Activation of adenosine A2A receptors inhibits neutrophil transuroepithelial migration.

Authors:  Susanne Säve; Camilla Mohlin; Ravi Vumma; Katarina Persson
Journal:  Infect Immun       Date:  2011-06-06       Impact factor: 3.441

5.  Inhibition of adenosine kinase by phosphonate and bisphosphonate derivatives.

Authors:  Jae Park; Bhag Singh; Radhey S Gupta
Journal:  Mol Cell Biochem       Date:  2006-02       Impact factor: 3.396

6.  Adenosine deaminase from camel tick Hyalomma dromedarii: purification and characterization.

Authors:  Tarek M Mohamed
Journal:  Exp Appl Acarol       Date:  2006-11-07       Impact factor: 2.132

Review 7.  Immunological alterations mediated by adenosine during host-microbial interactions.

Authors:  Ioannis Drygiannakis; Peter B Ernst; David Lowe; Ian J Glomski
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

8.  Adenosine receptor A2A deficiency in leukocytes increases arterial neointima formation in apolipoprotein E-deficient mice.

Authors:  Huan Wang; Weiyu Zhang; Rong Tang; Chuhong Zhu; Christoph Bucher; Bruce R Blazar; Jian-Guo Geng; Chunxiang Zhang; Joel Linden; Chaodong Wu; Yuqing Huo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-18       Impact factor: 8.311

9.  Mammalian mismatches in nucleotide metabolism: implications for xenotransplantation.

Authors:  Zain Khalpey; Ada H Y Yuen; Marialuisa Lavitrano; Christopher G A McGregor; Kameljit K Kalsi; Magdi H Yacoub; Ryszard T Smolenski
Journal:  Mol Cell Biochem       Date:  2007-07-27       Impact factor: 3.396

10.  Staphylococcus aureus synthesizes adenosine to escape host immune responses.

Authors:  Vilasack Thammavongsa; Justin W Kern; Dominique M Missiakas; Olaf Schneewind
Journal:  J Exp Med       Date:  2009-09-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.